Stock listing

OTC:HEPA Hepion Pharmaceuticals, Inc. Stock

Follow Hepion Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · OTC:HEPA

$0.119 USD +0.023 (+24.6%)

Close on Nov 20, 2026

Past year +67.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.087 – $0.119 USDNov 20, 2026
Volume
3,803 sharesNov 20, 2026
Market cap
$14.63M USDAt the close on Nov 20, 2026 · price × 123.2M shares outstanding
52-week range
$0.034 – $0.220 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$3,665 USDMedian day 18,200 shares · 1 day with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Hepion Pharmaceuticals, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:HEPA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.119+0.023+24.6%$0.116$0.119$0.0873,803
$0.095-0.020-17.1%$0.095$0.096$0.09515
$0.1150.0000.0%$0.115$0.115$0.11553
$0.115+0.014+13.9%$0.110$0.135$0.10532,900
$0.101-0.013-11.4%$0.103$0.125$0.09054,200
$0.114-0.026-18.6%$0.113$0.114$0.1132,200
$0.140+0.010+7.7%$0.120$0.140$0.12045,700
$0.130+0.012+10.2%$0.108$0.130$0.108700
$0.118-0.013-9.9%$0.118$0.118$0.11313,000
$0.131+0.009+7.4%$0.116$0.131$0.1142,400
$0.122+0.007+6.1%$0.140$0.140$0.10569,300
$0.115-0.020-14.8%$0.135$0.143$0.115166,600
$0.135-0.009-6.2%$0.144$0.144$0.13098,400
$0.144-0.011-7.1%$0.145$0.145$0.144700
$0.155-0.025-13.9%$0.179$0.179$0.15520,300
$0.180+0.040+28.6%$0.190$0.210$0.16256,300
$0.140-0.010-6.7%$0.135$0.220$0.135100,500
$0.150+0.012+8.7%$0.134$0.150$0.12023,700
$0.138+0.007+5.3%$0.131$0.138$0.131700
$0.131-0.009-6.4%$0.131$0.131$0.1312,400
$0.140+0.005+3.7%$0.150$0.155$0.14051,800
$0.135+0.012+9.8%$0.130$0.136$0.13048,300
$0.123+0.003+2.5%$0.118$0.130$0.1165,100
$0.120+0.018+17.6%$0.134$0.140$0.11518,200
$0.102-0.002-1.9%$0.100$0.112$0.10018,300
$0.104+0.006+6.1%$0.110$0.110$0.0921,100
$0.098+0.007+7.7%$0.090$0.098$0.0904,100
$0.091+0.030+49.2%$0.119$0.119$0.07510,400
$0.061-0.063-50.8%$0.120$0.134$0.06172,100
$0.124+0.004+3.3%$0.122$0.132$0.12020,100
$0.120-0.005-4.0%$0.120$0.120$0.12017,100
$0.125+0.005+4.2%$0.085$0.128$0.08524,900
$0.1200.0000.0%$0.120$0.120$0.1200
$0.120+0.020+20.0%$0.103$0.120$0.10321,600
$0.100+0.019+23.5%$0.100$0.100$0.100200
$0.081-0.019-19.0%$0.095$0.098$0.08126,500
$0.100-0.014-12.3%$0.120$0.120$0.09534,800
$0.114+0.004+3.6%$0.100$0.114$0.10018,200
$0.110+0.030+37.5%$0.075$0.123$0.07593,700
$0.080-0.007-8.0%$0.080$0.080$0.08017,900
$0.087+0.011+14.5%$0.079$0.104$0.049386,400
$0.076+0.013+20.6%$0.076$0.076$0.0761,100
$0.063-0.016-20.3%$0.066$0.075$0.05952,600
$0.079-0.001-1.3%$0.074$0.079$0.0742,200
$0.080+0.003+3.9%$0.063$0.080$0.06316,500
$0.077+0.005+6.9%$0.077$0.077$0.0775,100
$0.072+0.003+4.3%$0.067$0.081$0.0673,900
$0.069-0.010-12.7%$0.063$0.069$0.0632,700
$0.0790.0000.0%$0.079$0.079$0.0791
$0.079+0.008+11.3%$0.066$0.079$0.0664,000
$0.071-0.004-5.3%$0.059$0.073$0.05590,300
$0.075+0.018+31.6%$0.074$0.076$0.05639,300
$0.057-0.031-35.2%$0.080$0.080$0.0578,400
$0.0880.0000.0%$0.076$0.088$0.05837,200
$0.088+0.022+33.3%$0.066$0.088$0.06624,800
$0.066-0.005-7.0%$0.083$0.083$0.06621,600
$0.071-0.004-5.3%$0.080$0.080$0.06417,300
$0.075-0.005-6.3%$0.088$0.090$0.07544,100
$0.080-0.015-15.8%$0.075$0.090$0.07541,100
$0.095+0.042+79.2%$0.054$0.095$0.053271,500
$0.053-0.012-18.5%$0.064$0.064$0.0537,800
$0.065-0.009-12.2%$0.075$0.075$0.0547,800
$0.074+0.013+21.3%$0.052$0.074$0.05219,200
$0.061-0.014-18.7%$0.065$0.065$0.06171,300
$0.0750.0000.0%$0.071$0.075$0.0716,800
$0.0750.0000.0%$0.075$0.075$0.07526

Splits

4 splits since 2018 · OTC:HEPA · every price before a split is adjusted for it

DayRatioWhat
1-for-50Consolidation
1-for-20Consolidation
1-for-70Consolidation
1-for-8Consolidation
Ticker
OTC:HEPA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Latest news

All Hepion Pharmaceuticals, Inc. news

Hepion Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
3 in the last 12 months · 3 in all · newest Oct 26, 2026 · oldest 2026
Decks
42 decks · latest Jul 22, 2024

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$10.37M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
-1.02

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Hepion Pharmaceuticals, Inc. · OTC:HEPAUS$14.63MUS$10.37Mn/an/an/an/an/an/a-1.02
Quoin Pharmaceuticals. Ltd · NASDAQ:QNRXUS$15.76M−US$17.43Mn/an/an/a0.6×n/a0.0×0.68
Celularity Inc. · NASDAQ:CELUUS$15.02MUS$50.46Mn/a2.7×n/an/a−117.3%n/a1.47
Context Therapeutics Inc. · NASDAQ:CNTXUS$14.70M−US$19.50Mn/an/an/a0.5×n/a0.0×0.99
NewcelX Ltd. · NASDAQ:NCELUS$14.67MUS$14.35Mn/an/an/a2.4×n/a0.1×0.89
Vectorite Biomedical, Inc. · TPEX:4170US$14.21MUS$9.17M4.9×4.9×n/a0.9×156.6%0.0×n/a
Estrella Immunopharma, Inc. · NASDAQ:ESLAUS$14.11MUS$14.01Mn/an/an/an/an/an/a1.31
Citius Pharmaceuticals, Inc. · NASDAQ:CTXRUS$13.96M−US$3.05Mn/an/an/a0.2×n/a0.0×1.71
TaiwanJ Pharmaceuticals Co., Ltd. · TPEX:6549US$13.69MUS$11.86Mn/an/an/a7.0×n/a0.0×n/a
Actuate Therapeutics, Inc. · NASDAQ:ACTUUS$13.60MUS$11.50Mn/an/an/an/an/an/a1.75
BeyondSpring, Inc. · NASDAQ:BYSIUS$13.57MUS$12.99M0.3×n/an/a0.9×n/a0.0×1.31
Median of the othersUS$14.16MUS$11.68M2.6×3.8×0.9×19.6%0.0×1.31

Team and board

Officers

OfficerRole
Sireesh AppajosyulaChief Executive Officer and Director
Gary StetzChief Financial Officer and Director
Chase LoPrioreVP, Corporate Development & Director
Bobbi Fox-CaminitiDirector of Operations
Vincent LoPrioreExecutive Chairman and Director

Board

DirectorRole
Michael PurcellIndependent Director & Audit Chair
Vincent LoPrioreExecutive Chairman and Director
Chase LoPrioreVP, Corporate Development & Director
Danina FisherIndependent Director
Gary StetzChief Financial Officer and Director
James Gordon LiddyIndependent Director
Sireesh AppajosyulaChief Executive Officer and Director

Events

QuarterResultsShare move
Q2 2025Aug 14, 2025
Q1 2025Apr 8, 2025+10.9%
Q4 2024Feb 26, 2025−7.4%
Q3 2024Nov 18, 2024 · Before open+1.1%
Q2 2024Aug 13, 2024 · After close+11.8%
Q1 2024Apr 16, 2024 · After close+4.4%
Q4 2023Jan 6, 2024 · Before open+13.1%
Q3 2023Nov 20, 2023 · After close−1.3%
Q2 2023Aug 14, 2023 · After close+1.4%
Q1 2023May 12, 2023 · After close+1.8%
All 19 quarters
QuarterResultsShare move
Q4 2022Mar 1, 2023−9.1%
Q3 2022Nov 14, 2022 · After close+9.9%
Q2 2022Aug 15, 2022 · After close−1.5%
Q1 2022May 16, 2022 · After close−4.2%
Q4 2021Mar 2, 2022−0.8%
Quarter to Sep 30, 2021Nov 15, 2021 · After close−3.4%
Quarter to Jun 30, 2021Aug 16, 2021 · After close−0.7%
Quarter to Mar 31, 2021May 14, 2021 · After close+6.9%
Quarter to Dec 31, 2020Mar 31, 2021 · After close+8.2%

Open Events

Decks

DeckKindSlidesDate
Merger or Acquisition (July 2024)Merger or acquisition28 slidesJul 22, 2024
Investor Presentation (October 2023)Investor deck36 slidesOctober 2023
Investor Presentation (August 2023)Investor deck38 slidesAugust 2023
Investor Presentation (July 2023)Investor deck38 slidesJul 24, 2023
Investor Presentation (July 2023)Investor deck38 slidesJuly 2023
Investor Presentation (May 2023)Investor deck37 slidesMay 2023
Investor Presentation (April 2023)Investor deck38 slidesApril 2023
Investor Presentation (February 2023)Investor deck39 slidesFebruary 2023
Investor Presentation (November 2022)Investor deck34 slidesNovember 2022
Investor Presentation (November 2022)Investor deck34 slidesNovember 2022
All 42 decks
DeckKindSlidesDate
Investor Presentation (October 2022)Investor deck34 slidesOct 17, 2022
Investor Presentation (October 2022)Investor deck34 slidesOct 14, 2022
Investor Presentation (September 2022)Investor deck40 slidesSeptember 2022
2nd World Congress on Alcohol and Alcoholism 2022Conference19 slidesSeptember 2022
Investor Presentation (July 2022)Investor deck40 slidesJuly 2022
Corporate Update (May 2022)Corporate update31 slidesMay 27, 2022
Investor Presentation (May 2022)Investor deck36 slidesMay 2022
Investor Presentation (January 2022)Investor deck28 slidesJanuary 2022
Investor Presentation (December 2021)Investor deck28 slidesDecember 2021
Investor Presentation (October 2021)Investor deck28 slidesOctober 2021
Corporate Update (September 2021)Corporate update31 slidesSep 13, 2021
Investor Presentation (June 2021)Investor deck20 slidesJune 2021
IPO Roadshow (February 2021)IPO roadshow21 slidesFeb 12, 2021
Investor Presentation (January 2021)Investor deck20 slidesJanuary 2021
Investor Presentation (December 2020)Investor deck23 slidesDecember 2020
4th NASH Summit 2020Conference22 slidesDecember 2020
Investor Presentation (November 2020)Investor deck25 slidesNov 18, 2020
Investor Presentation (October 2020)Investor deck21 slidesOct 16, 2020
Investor Presentation (June 2020)Investor deck26 slidesJun 26, 2020
Investor Presentation (June 2020)Investor deck25 slidesJun 12, 2020
Investor Presentation (May 2020)Investor deck22 slidesMay 23, 2020
Investor Presentation (March 2020)Investor deck21 slidesMar 11, 2020
Investor Presentation (March 2020)Investor deck21 slidesMar 9, 2020
Investor Presentation (March 2020)Investor deck22 slidesMarch 2020
Investor Presentation (February 2020)Investor deck21 slidesFebruary 2020
Investor Presentation (December 2019)Investor deck19 slidesDecember 2019
Investor Presentation (October 2019)Investor deck21 slidesOctober 2019
Investor Presentation (September 2019)Investor deck20 slidesSeptember 2019
ContraVir Pharmaceuticals — Investor Presentation (June 2019)Investor deck20 slidesJun 11, 2019
ContraVir Pharmaceuticals — Investor Presentation (January 2019)Investor deck32 slidesJan 2, 2019
ContraVir Pharmaceuticals — IPO Roadshow (June 2018)IPO roadshow19 slidesJun 5, 2018
ContraVir Pharmaceuticals — Investor Presentation (May 2015)Investor deck27 slidesMay 28, 2015

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2017
Revenue0000
Research and development445.5K11.8M35.6M33.3M20.4M12.0M3.18M7.59M13.4M13.7M
Operating income-4.16M-19.3M-48.4M-45.5M-30.4M-20.1M-7.77M-14.6M-20.6M-21.0M
Depreciation and amortization30.8K67.1K77.5K86.1K34.5K26.7K18.8K28.0K
EBITDA-19.3M-48.4M-45.4M-30.3M-20.1M-7.74M-14.6M-21.0M
Interest expense9.46K10.2K8.86K31.2K555.0K339.2K
Income before tax-8.28M-16.2M-49.3M-45.1M-32.7M-20.3M-7.95M-9.99M-15.0M-16.8M
Income tax-2.97M-409.0K-2.88M030.6K-908.7K-536.0K-1.95M-1.91M
Net income-8.28M-13.2M-48.9M-42.2M-32.7M-20.4M-7.04M-9.45M-13.1M-14.9M
Earnings per share, basic-0.88-107.35-616.07-11.90-0.47-2.10-5.95-97.35-1.34-2.04
Earnings per share, diluted-0.88-107.35-616.07-11.90-0.47-2.10-6.11-1.39-2.41

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2017
Cash and equivalents1.83M406.4K14.8M51.2M91.3M40.7M13.9M2.83M5.95M13.0M
Current assets3.07M1.61M17.5M56.5M97.5M42.6M14.4M2.97M6.06M13.2M
Property, plant and equipment29.5K81.6K152.8K108.4K57.2K32.4K56.6K67.6K
Goodwill01.87M1.87M1.87M1.87M1.87M1.87M
Total assets3.07M1.61M18.1M60.2M103.6M48.6M20.6M8.19M11.3M18.4M
Accounts payable167.8K220.2K2.35M2.67M2.45M3.72M491.6K748.4K1.56M1.63M
Current liabilities299.4K3.14M5.29M7.89M8.21M4.66M1.61M2.85M2.60M2.94M
Total debt0
Total liabilities402.4K3.48M10.8M10.4M10.6M8.12M4.99M6.21M7.55M9.33M
Shareholders' equity2.67M-1.86M7.28M49.9M93.0M40.5M15.6M1.72M3.70M9.06M
Shares outstanding11.6M139.2K96.4K3.81M76.2M32.0M3.76M247.0K9.79M75.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-3.27M-18.2M-40.9M-35.0M-31.2M-16.2M-7.57M-15.6M-19.2M
Capital spending-14.3K-16.3K-130.4K-88.0K-51.5K-14.7K
Free cash flow-40.9M-35.0M-31.4M-16.3M-7.62M-19.2M
Cash from investing-132.1K-600.0K-14.3K-14.1K-130.4K-85.8K-51.5K900-14.7K
Cash from financing4.83M4.35M4.49M-5.14M82.0M43.1M18.7M12.5M24.8M
Change in cash1.42M-14.4M-36.4M-40.2M50.6M26.8M11.1M-3.12M5.58M

Open Financials

Filings

FilingDateTypeFiled with
10-Q/A · Quarterly report, amendedNov 17, 2026Quarterly reportSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
4 · Change in ownershipOct 27, 2026Insider tradeSEC
4 · Change in ownershipOct 27, 2026Insider tradeSEC
4 · Change in ownershipOct 27, 2026Insider tradeSEC
4 · Change in ownershipOct 27, 2026Insider tradeSEC
4 · Change in ownershipOct 27, 2026Insider tradeSEC
4 · Change in ownershipOct 27, 2026Insider tradeSEC
4 · Change in ownershipOct 27, 2026Insider tradeSEC
4 · Change in ownershipOct 27, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13D · Big-stake noticeOct 26, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 21, 2026Big-stake noticeSEC
3 · Initial statement of ownershipOct 21, 2026Insider tradeSEC
S-8 · Registration statement for employee plansOct 14, 2026Offer documentSEC
8-K · Current reportOct 9, 2026Acquisition or disposalSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
8-K · Current reportOct 2, 2026Current reportSEC
8-K · Current reportSep 28, 2026Current reportSEC
3 · Initial statement of ownershipSep 16, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeSep 15, 2026Big-stake noticeSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
DEF 14CSep 10, 2026Meeting noticeSEC
4 · Change in ownershipSep 10, 2026Insider tradeSEC
8-K · Current reportSep 8, 2026Material contractSEC
PRE 14CAug 28, 2026Meeting noticeSEC
8-K · Current reportAug 27, 2026Material contractSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 21, 2026Insider tradeSEC
8-K · Current reportAug 20, 2026Management or board changeSEC
SCHEDULE 13D · Big-stake noticeAug 20, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 20, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeAug 20, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 7, 2026Insider tradeSEC
S-8 · Registration statement for employee plansAug 7, 2026Offer documentSEC
SCHEDULE 13D · Big-stake noticeAug 7, 2026Big-stake noticeSEC
DAug 5, 2026Other filingsSEC
8-K · Current reportAug 4, 2026Material contractSEC
3 · Initial statement of ownershipJul 10, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 8, 2026Insider tradeSEC
8-K · Current reportJul 2, 2026Management or board changeSEC
8-K · Current reportJun 17, 2026Meeting outcomeSEC
3 · Initial statement of ownershipMay 26, 2026Insider tradeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
SCHEDULE 13D · Big-stake noticeMay 1, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
4 · Change in ownershipApr 27, 2026Insider tradeSEC
4 · Change in ownershipApr 27, 2026Insider tradeSEC
4 · Change in ownershipApr 27, 2026Insider tradeSEC
4 · Change in ownershipApr 27, 2026Insider tradeSEC
DApr 22, 2026Other filingsSEC
8-K · Current reportApr 22, 2026Material contractSEC
8-K · Current reportApr 14, 2026Material contractSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2026Insider tradeSEC
8-K · Current reportMar 18, 2026Management or board changeSEC
10-K · Annual reportMar 11, 2026Annual reportSEC
8-K · Current reportMar 3, 2026Material contractSEC
8-K · Current reportJan 15, 2026Management or board changeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
25-NSEJul 22, 2025Other filingsSEC
8-K · Current reportJun 30, 2025Management or board changeSEC
8-K · Current reportJun 12, 2025Meeting outcomeSEC
8-K · Current reportJun 9, 2025Management or board changeSEC
8-K · Current reportMay 30, 2025Material contractSEC
10-Q · Quarterly reportMay 19, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
NT 10-Q · Late filing noticeMay 15, 2025Explanation requestSEC
8-K · Current reportMay 12, 2025Current reportSEC
8-K · Current reportMay 6, 2025Material contractSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
UPLOAD · Letter from the SECApr 24, 2025Other filingsSEC
PRER14AApr 23, 2025Other filingsSEC
8-K · Current reportApr 17, 2025Current reportSEC
PRE 14A · Preliminary proxy statementApr 17, 2025Meeting noticeSEC
10-K · Annual reportApr 8, 2025Annual reportSEC
8-K/A · Current report, amendedApr 4, 2025Current reportSEC
NT 10-K · Late filing noticeMar 31, 2025Explanation requestSEC
8-K · Current reportMar 20, 2025Current reportSEC
8-K · Current reportMar 19, 2025Current reportSEC
8-K · Current reportMar 10, 2025Meeting outcomeSEC
8-K · Current reportMar 4, 2025Current reportSEC
DEF 14A · Proxy statementFeb 7, 2025Meeting noticeSEC
ARS/A · Annual report to shareholders, amendedFeb 7, 2025Annual reportSEC
ARS · Annual report to shareholdersFeb 7, 2025Annual reportSEC
PRE 14A · Preliminary proxy statementJan 27, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeJan 27, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 24, 2025Big-stake noticeSEC
424B4 · ProspectusJan 23, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 22, 2025Other filingsSEC
S-1MEF · Registration of more shares for the same offeringJan 21, 2025Offer documentSEC
CORRESP · Letter to the SECJan 17, 2025Other filingsSEC
CORRESP · Letter to the SECJan 17, 2025Other filingsSEC
CORRESP · Letter to the SECJan 15, 2025Other filingsSEC
CORRESP · Letter to the SECJan 15, 2025Other filingsSEC
8-K · Current reportJan 15, 2025Current reportSEC
CORRESP · Letter to the SECJan 14, 2025Other filingsSEC
CORRESP · Letter to the SECJan 14, 2025Other filingsSEC
S-1/A · Registration statement, amendedJan 14, 2025Offer documentSEC
10-K/A · Annual report, amendedJan 13, 2025Annual reportSEC
UPLOAD · Letter from the SECJan 2, 2025Other filingsSEC
S-1 · Registration statementDec 26, 2024Offer documentSEC
8-K · Current reportDec 11, 2024Current reportSEC
DEFA14A · Additional proxy materialDec 5, 2024Meeting noticeSEC
DEFA14A · Additional proxy materialDec 2, 2024Meeting noticeSEC
425Nov 21, 2024Other filingsSEC
8-K · Current reportNov 21, 2024Current reportSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
425Sep 5, 2024Other filingsSEC
8-K · Current reportSep 5, 2024Current reportSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
425Aug 7, 2024Other filingsSEC
8-K · Current reportAug 7, 2024Management or board changeSEC
DJul 23, 2024Other filingsSEC
425Jul 22, 2024Other filingsSEC
8-K · Current reportJul 22, 2024Material contractSEC
EFFECT · Notice that a registration is effectiveJul 16, 2024Other filingsSEC
424B3 · ProspectusJul 15, 2024Offer documentSEC
CORRESP · Letter to the SECJul 12, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 12, 2024Other filingsSEC
S-1 · Registration statementJul 11, 2024Offer documentSEC
10-K/A · Annual report, amendedJun 24, 2024Annual reportSEC
10-Q · Quarterly reportMay 21, 2024Quarterly reportSEC
NT 10-Q · Late filing noticeMay 15, 2024Explanation requestSEC
10-K · Annual reportApr 16, 2024Annual reportSEC
NT 10-K · Late filing noticeApr 1, 2024Explanation requestSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 6, 2024Insider tradeSEC
8-K · Current reportMar 6, 2024Management or board changeSEC
4 · Change in ownershipFeb 21, 2024Insider tradeSEC
4 · Change in ownershipFeb 21, 2024Insider tradeSEC
4 · Change in ownershipFeb 21, 2024Insider tradeSEC
4 · Change in ownershipFeb 21, 2024Insider tradeSEC
8-K · Current reportFeb 20, 2024Management or board changeSEC
8-K · Current reportFeb 16, 2024Material contractSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
8-K · Current reportFeb 7, 2024Management or board changeSEC
8-K · Current reportJan 3, 2024Current reportSEC
8-K · Current reportDec 7, 2023Management or board changeSEC
4 · Change in ownershipNov 28, 2023Insider tradeSEC
10-Q · Quarterly reportNov 20, 2023Quarterly reportSEC
NT 10-Q · Late filing noticeNov 14, 2023Explanation requestSEC
EFFECT · Notice that a registration is effectiveNov 9, 2023Other filingsSEC
CORRESP · Letter to the SECNov 6, 2023Other filingsSEC
UPLOAD · Letter from the SECNov 3, 2023Other filingsSEC
S-1 · Registration statementOct 31, 2023Offer documentSEC
DOct 3, 2023Other filingsSEC
8-K · Current reportOct 2, 2023Material contractSEC
424B5 · ProspectusOct 2, 2023Offer documentSEC
4 · Change in ownershipSep 20, 2023Insider tradeSEC
4 · Change in ownershipSep 19, 2023Insider tradeSEC
4 · Change in ownershipSep 18, 2023Insider tradeSEC
8-K · Current reportSep 6, 2023Management or board changeSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportJul 24, 2023Current reportSEC
8-K · Current reportJul 21, 2023Material contractSEC
424B5 · ProspectusJul 21, 2023Offer documentSEC
S-8 · Registration statement for employee plansJul 14, 2023Offer documentSEC
8-K · Current reportJun 22, 2023Meeting outcomeSEC
8-K · Current reportMay 22, 2023Current reportSEC
10-Q · Quarterly reportMay 12, 2023Quarterly reportSEC
8-K · Current reportMay 10, 2023Current reportSEC
ARS · Annual report to shareholdersApr 28, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
10-K · Annual reportApr 10, 2023Annual reportSEC
NT 10-K · Late filing noticeMar 31, 2023Explanation requestSEC
8-K · Current reportDec 15, 2022Meeting outcomeSEC
DEF 14A · Proxy statementNov 21, 2022Meeting noticeSEC
DNov 15, 2022Other filingsSEC
10-Q · Quarterly reportNov 14, 2022Quarterly reportSEC
PRE 14A · Preliminary proxy statementNov 9, 2022Meeting noticeSEC
8-K · Current reportNov 8, 2022Material contractSEC
8-K · Current reportOct 17, 2022Current reportSEC
10-Q · Quarterly reportAug 15, 2022Quarterly reportSEC
8-K · Current reportAug 5, 2022Meeting outcomeSEC
DEFA14A · Additional proxy materialJul 26, 2022Meeting noticeSEC
DEFA14A · Additional proxy materialJul 22, 2022Meeting noticeSEC
3 · Initial statement of ownershipJul 20, 2022Insider tradeSEC
3 · Initial statement of ownershipJul 5, 2022Insider tradeSEC

This page holds 200 of 725 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Hepion Pharmaceuticals, Inc.’s releases

Common shares
123,220,476
Fully diluted
123,220,476

Fully diluted

LineShares
Common shares123,220,476

Share count over time

CountShares
Nov 22, 2026123,220,476

Open Cap table

Shareholders

HolderStakeSharesDate
Gravitas Collective Corp.19.90%25MOct 6, 2026
Kenneth Rickel7.20%7.25MOct 20, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Tamar D Howson
Other companies: Immunic, Inc. (Director · Since at least Oct 11, 2019); Cue Biopharma, Inc. (Director · Sep 17, 2020 – Jan 3, 2023 · Past); Lite Strategy, Inc. (Director · Jul 1, 2019 – Sep 29, 2023 · Past); VivoSim Labs, Inc. (Director · Jun 5, 2013 – Jul 26, 2018 · Past); Warner Chilcott PLC (Director · May 7, 2013 – Sep 30, 2013 · Past); Aradigm Corporation (Director · Nov 3, 2010 – May 25, 2012 · Past); Soligenix, Inc. (Director · Sep 23, 2010 – Jun 22, 2011 · Past); Oncotelic Therapeutics Inc (Director · Apr 2, 2010 – May 28, 2015 · Past); Idenix Pharmaceuticals Inc (Director · Mar 30, 2010 – Aug 5, 2014 · Past); Lexicon Pharmaceuticals, Inc. (EVP of Bus Dev · Apr 2, 2007 – Feb 7, 2008 · Past); Bristol-Myers Squibb Company (SVP, Corp & Bus Development · Mar 7, 2006 – Dec 1, 2006 · Past)
Director · Dec 14, 2016 – Apr 10, 2017 · Past
James Sapirstein
Other companies: INmune Bio Inc. (Director · Since at least Sep 8, 2026); Cocrystal Pharma, Inc. (Chief Executive Officer · Since at least Jun 3, 2026); ZyVersa Therapeutics, Inc. (Chairman and CEO – 8 Prime Biosciences · Since at least Jan 5, 2023); Onconetix, Inc. (Director · Feb 23, 2022 – Sep 26, 2024 · Past); Blue Water Acquisition Corp (Director · Dec 15, 2020 – Dec 15, 2020 · Past); Marizyme, Inc. (Interim CEO, Director · Sep 10, 2020 – Mar 5, 2021 · Past); GridAI Technologies Corp. (Chairman and CEO, Director · Oct 8, 2019 – Jul 2, 2024 · Past); Lunai Bioworks Inc. (Director · Mar 6, 2018 – Jun 25, 2024 · Past); ProBility Media Corp. (Director · Nov 8, 2016 – Feb 15, 2017 · Past); RespireRx Pharmaceuticals Inc (Director · Mar 31, 2016 – Dec 9, 2017 · Past)
Chief Executive Officer, Director · Mar 19, 2014 – Jan 3, 2018 · Past
John Brancaccio
Other companies: Tiziana Life Sciences Ltd (Non-Executive Director · Since at least Nov 5, 2026); OKYO Pharma Limited (Director · Since at least May 16, 2022); Accustem Sciences Inc (Board Member · Since at least Dec 1, 2021); Cardiff Oncology, Inc. (Director · Jan 23, 2012 – Mar 9, 2022 · Past); Synergy Pharmaceuticals Inc (Director · Aug 3, 2011 – Jul 4, 2018 · Past); Callisto Pharmaceuticals Inc (Director · Dec 18, 2008 – Jan 17, 2013 · Past)
Chairman, Director · Oct 7, 2013 – Feb 19, 2024 · Past
Gary Jacob
Other companies: OKYO Pharma Limited (Chief Development Officer/Director · Since at least May 16, 2022); Virpax Pharmaceuticals, Inc. (Director · Feb 16, 2021 – Jan 1, 2022 · Past); Callisto Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 17, 2013 – Jan 17, 2013 · Past); Cardiff Oncology, Inc. (Director · Jan 23, 2012 – Mar 23, 2021 · Past); Synergy Pharmaceuticals Inc (Executive Chairman, Director · Dec 6, 2011 – Jun 15, 2018 · Past)
Director · Oct 7, 2013 – Feb 19, 2024 · Past
Bernard Denoyer
Other companies: OKYO Pharma Limited (Non-Executive Director · Since at least May 16, 2022); Callisto Pharmaceuticals Inc (Senior Vice President, Finance · Jan 17, 2013 – Jan 17, 2013 · Past); Synergy Pharmaceuticals Inc (Senior Vice President, Finance · Aug 3, 2011 – Jun 24, 2016 · Past)
Chief Financial Officer · Oct 7, 2013 – Apr 3, 2014 · Past
Christopher McGuigan
Other companies: Cardiff Oncology, Inc. (Director · Jan 14, 2013 – Feb 14, 2013 · Past); Synergy Pharmaceuticals Inc (Director · Aug 3, 2011 – Jul 24, 2015 · Past); Inhibitex Inc (Director · Sep 19, 2007 – Feb 13, 2012 · Past)
Director · Oct 7, 2013 – Dec 3, 2014 · Past
Michael Purcell
Other companies: International Money Express, Inc. (Director · Since at least Jul 26, 2018); Tabula Rasa HealthCare Inc (Director · Jul 18, 2018 – Nov 3, 2023 · Past); Patriot National Inc (Director · Jan 1, 2017 – Jan 4, 2017 · Past)
Independent Director & Audit Chair · Since at least Mar 5, 2024
Gary Stetz
Other companies: Canton Strategic Holdings, Inc. (Independent Director · Since at least Apr 28, 2025); BCB Bancorp, Inc. (nj) (Director · Oct 14, 2011 – Mar 14, 2018 · Past)
Chief Financial Officer and Director · Since at least Mar 16, 2026
Thomas Phd Adams
Other companies: Cardiff Oncology, Inc. (Executive Chairman, Director · Jan 4, 2016 – Jun 17, 2020 · Past); Synergy Pharmaceuticals Inc (Director · Jul 24, 2015 – Jul 3, 2018 · Past)
Director · Sep 20, 2016 – May 18, 2021 · Past
Arnold Lippa
Other companies: RespireRx Pharmaceuticals Inc (Exec. Chairman & CSO, Director · Jan 29, 2016 – Sep 30, 2020 · Past)
Director · Nov 30, 2015 – May 18, 2021 · Past
All 25 people
PersonSeat
James Gordon Liddy
Other companies: Canton Strategic Holdings, Inc. (Director · Since at least Jun 11, 2025)
Director · Since at least Aug 19, 2026
John T Cavan
Other companies: Aegerion Pharmaceuticals Inc (VP & Chief Accounting Officer · Oct 21, 2010 – Oct 21, 2010 · Past)
Chief Financial Officer · Apr 1, 2016 – May 18, 2021 · Past
Peter Wijngaard
Other companies: The Medicines Company (Chief Development Officer · May 30, 2019 – Jan 6, 2020 · Past)
Director · Jun 10, 2020 – Nov 24, 2023 · Past
Robert T Foster
Other companies: Aurinia Pharmaceuticals Inc (Director · Sep 21, 2023 – Sep 21, 2023 · Past)
CEO and Director, Director · Jun 10, 2016 – Sep 18, 2023 · Past
Sireesh Appajosyula
Other companies: Canton Strategic Holdings, Inc. (CEO · Since at least Jan 11, 2022)
Chief Executive Officer and Director · Since at least Mar 16, 2026
Vincent LoPriore
Other companies: Canton Strategic Holdings, Inc. (Director · Since at least Apr 9, 2025)
Executive Chairman and Director · Since at least Mar 16, 2026
William Karl Hornung
Other companies: CervoMed Inc. (Chief Financial Officer · Sep 21, 2018 – Jan 27, 2022 · Past)
Chief Financial Officer · Jun 23, 2014 – Jun 4, 2015 · Past
Anand ReddiDirector · Jun 27, 2022 – Jun 27, 2022 · Past
Bobbi Fox-CaminitiDirector of Operations · Since at least Nov 5, 2026
Chase LoPrioreVP, Corporate Development & Director · Since at least Mar 16, 2026
Danina FisherIndependent Director · Since at least Jul 1, 2026
Gary S Stetz IIDirector · Since at least Jul 1, 2026
John Z Sullivan-BolyaiChief Medical Officer · Mar 2, 2016 – Jul 6, 2017 · Past
Kaouthar LbiatiDirector · Jun 27, 2022 – Feb 19, 2024 · Past
Timothy M BlockDirector · Nov 26, 2013 – Feb 19, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Hepion Pharmaceuticals, Inc.